The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. [electronic resource]
Producer: 20091224Description: 939-45 p. digitalISSN:- 1523-1755
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antineoplastic Agents -- adverse effects
- Aryl Hydrocarbon Receptor Nuclear Translocator -- genetics
- Carcinoma, Renal Cell -- drug therapy
- Drug Design
- Gene Expression Regulation, Neoplastic
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit -- genetics
- Kidney Neoplasms -- genetics
- Protein Kinase Inhibitors -- therapeutic use
- Protein Kinases -- drug effects
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- TOR Serine-Threonine Kinases
- Translational Research, Biomedical
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Von Hippel-Lindau Tumor Suppressor Protein -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
There are no comments on this title.
Log in to your account to post a comment.